162 related articles for article (PubMed ID: 38070124)
1. "Regulatory Sandboxes" Could Solve the Regulatory Problems Encountered in Europe and Arising from Innovation in Biological Medicinal Products.
Guerriaud M
Pharmaceut Med; 2024 Jan; 38(1):19-23. PubMed ID: 38070124
[TBL] [Abstract][Full Text] [Related]
2. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
3. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
Lehmann B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
[TBL] [Abstract][Full Text] [Related]
4. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
[TBL] [Abstract][Full Text] [Related]
5. [The regulatory framework for complementary and alternative medicines in Europe].
Knöss W; Stolte F; Reh K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
[TBL] [Abstract][Full Text] [Related]
6. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
7. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
8. [The use of nanotechnology in medicinal products in the light of European Union law].
Jurewicz M
Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
[TBL] [Abstract][Full Text] [Related]
9. Opportunities and hurdles to European market access for multi-herbal traditional Chinese medicine products: An analysis of EU regulations for combination herbal medicinal products.
Qu L; Li X; Xiong Y; Wang Z; Zhou Y; Zou W; Tang J; Wang M
Pharmacol Res; 2022 Dec; 186():106528. PubMed ID: 36332812
[TBL] [Abstract][Full Text] [Related]
10. Medicinal products in the European Union--between harmonization and divergence.
Lojko N
Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
[TBL] [Abstract][Full Text] [Related]
11. Comparison of new Brazilian legislation for the approval of advanced therapy medicinal products with existing systems in the USA, European Union and Japan.
Gomes KLG; da Silva RE; da Silva Junior JB; Novaes MRCG
Cytotherapy; 2022 May; 24(5):557-566. PubMed ID: 35227603
[TBL] [Abstract][Full Text] [Related]
12. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
Kuhlmann-Gottke J; Duchow K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
[TBL] [Abstract][Full Text] [Related]
13. Regulatory structures for gene therapy medicinal products in the European Union.
Klug B; Celis P; Carr M; Reinhardt J
Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
[TBL] [Abstract][Full Text] [Related]
14. Medicinal plants and their preparations in the European market: Why has the harmonization failed? The cases of St. John's wort, valerian, ginkgo, ginseng, and green tea.
Bilia AR; Costa MDC
Phytomedicine; 2021 Jan; 81():153421. PubMed ID: 33291029
[TBL] [Abstract][Full Text] [Related]
15. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
[TBL] [Abstract][Full Text] [Related]
16. Advanced therapy medicinal products: Regulatory framework, hospital and pharmaceutical circuits in Europe and France.
Mebarki M; Madelaine I; Larghero J; de Jorna R
Therapie; 2022; 77(2):185-190. PubMed ID: 34895758
[TBL] [Abstract][Full Text] [Related]
17. Post-marketing authorisation safety and efficacy surveillance of advanced therapy medicinal products in Brazil, the European Union, the United States and Japan.
Gomes KLG; da Silva RE; da Silva JB; Bosio CGP; Novaes MRCG
Cytotherapy; 2023 Oct; 25(10):1113-1123. PubMed ID: 37436339
[TBL] [Abstract][Full Text] [Related]
18. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J
Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383
[TBL] [Abstract][Full Text] [Related]
19. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
Martinac AI; Tomić S; Simicić M
Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
[TBL] [Abstract][Full Text] [Related]
20. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
